Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?

per Lowenstein, Pedro R., Castro, Maria G.
Publicat 2009

The Value of EGFRvIII as the Target for Glioma Vaccines

per Lowenstein, Pedro R., Castro, Maria G.
Publicat a Am Soc Clin Oncol Educ Book (2014)

Gene Therapy Continues to Make Progress: Clinical and Regulatory Perspectives

per Castro, Maria G., Lowenstein, Pedro R.
Publicat a Curr Gene Ther (2009)

Glioma trials and viral tribulations: can anything be concluded from non-controlled trials?

per Lowenstein, Pedro R., Castro, Maria G.
Publicat a J Neurol Neurosurg Psychiatry (2014)

The Long and Winding Road: from the high affinity choline uptake site to clinical trials for malignant brain tumors

per Lowenstein, Pedro R., Castro, Maria G.
Publicat a Adv Pharmacol (2016)

Multiple expressed endogenous glioma epitopes as novel vaccines for gliomas

per Lowenstein, Pedro R., Castro, Maria G.
Publicat a Clin Cancer Res (2016)

Evolutionary basis of a new approach for the treatment of malignant brain tumors: from mice to humans

per Lowenstein, Pedro R., Castro, Maria G.
Publicat a Clin Immunol (2017)

Microtubule targeting agents in glioma

per Calinescu, Anda-Alexandra, Castro, Maria G.
Publicat a Transl Cancer Res (2016)

Immunology of neurological gene therapy: How T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses

per Lowenstein, Pedro R., Kroeger, Kurt, Castro, Maria G.
Publicat 2007

ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability

per Koschmann, Carl, Lowenstein, Pedro R., Castro, Maria G.
Publicat a Mol Cell Oncol (2016)

Challenges in the evaluation, consent, ethics and history of early clinical trials – Implications of the Tuskegee ‘trial’ for safer and more ethical clinical trials

per Lowenstein, Pedro R, Lowenstein, Elijah D, Castro, Maria G
Publicat 2009

Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy

per Lowenstein, Pedro R, Baker, Gregory J, Castro, Maria G
Publicat a Oncoimmunology (2014)

Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!

per Castro, Maria G., Baker, Gregory J., Lowenstein, Pedro R.
Publicat a Clin Cancer Res (2014)

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

per Baker, Gregory J., Castro, Maria G., Lowenstein, Pedro R.
Publicat a J Vis Exp (2015)

Human gene therapy and imaging in neurological diseases

per Jacobs, Andreas H., Winkler, Alexandra, Castro, Maria G., Lowenstein, Pedro
Publicat 2005

Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Anti-glioma Cytotoxic and Memory T cells’ Functions

per Mineharu, Yohei, Kamran, Neha, Lowenstein, Pedro R, Castro, Maria G
Publicat a Mol Cancer Ther (2014)

Immature Myeloid Cells in the Tumor Microenvironment: Implications for Immunotherapy

per Kamran, Neha, Chandran, Mayuri, Lowenstein, Pedro R, Castro, Maria G
Publicat a Clin Immunol (2016)

Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts

per Assi, Hikmat, Candolfi, Marianela, Lowenstein, Pedro R., Castro, Maria G.
Publicat a Neuromethods (2012)

Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials

per Mineharu, Yohei, Castro, Maria G, Lowenstein, Pedro R, Sakai, Nobuyuki, Miyamoto, Susumu
Publicat 2013

Functional Assay to Assess T-cell Inhibitory Properties of Myeloid Derived Suppressor Cells (MDSCs) Isolated from the Tumor Microenvironment of murine Glioma Models

per Alghamri, Mahmoud S., Kamran, Neha, Kadiyala, Padma, Lowenstein, Pedro R., Castro, Maria G.
Publicat a Methods Enzymol (2019)